Top Four Conveyor Car Wash to Donate 100% of Proceeds to Charitable Organizations
THOMASTON, GA / ACCESS Newswire / August 1, 2025 / Tidal Wave Auto Spa is pleased to announce its 17th annual Charity Day event will be held on Friday, September 19, 2025. As part of the company’s long-standing commitment to giving back, Tidal Wave will donate 100% of the proceeds made during the one-day philanthropic event to local charities and non-profit organizations.
Over the event’s 16-year history, Tidal Wave Auto Spa has donated over $2 million to charitable organizations, with $686,353 raised at last year’s event. 2025 is set to be the largest Charity Day event yet, with 295 participating locations across the company’s 30-state footprint.
“Since its inception, Charity Day has represented a core value of our organization – supporting the communities that support us,” said founder and CEO Scott Blackstock. “It is deeply fulfilling to see the positive impact we can make within these local organizations, and our team members look forward to participating in this tradition year after year.”
Before the September 19th event, each Tidal Wave location selects a local charity or non-profit organization to partner with, which will be awarded 50% of the proceeds, plus any cash donations made during the one-day event. Local organizations will be on-site during Charity Day to share more about their mission and engage with the community. The remaining 50% of proceeds are awarded to the company’s longtime corporate philanthropic partner, Annandale Village, a non-profit organization dedicated to providing progressive life assistance to adults with developmental disabilities.
Tidal Wave Auto Spa is dedicated to making a positive difference in the communities it serves and was honored as a Champion of Charity by Professional Carwashing & Detailing. Beyond its annual Charity Day event, the company also gives back year-round through its fundraising program, which has helped raise over $5 million for local schools, organizations, churches, civic groups, and more.
Tidal Wave Auto Spa was founded over 20 years ago in Thomaston, GA, by husband and wife, Scott and Hope Blackstock. What started as a small-town self-service car wash business evolved into the first conveyor car wash open in Georgia and is now the fourth-largest conveyor car wash company in the nation, with 297 locations spanning 30 states. Tidal Wave is committed to providing every customer an exceptional car wash experience through industry-leading car care technology, clean and attractive locations, and outstanding customer service. Tidal Wave is committed to making a positive impact in the communities it serves, raising over $7 million for local programs, service organizations, and non-profit organizations through the company’s fundraising program and annual philanthropic Charity Day event.
Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13)
Updates 2025 projected revenue range to $1.5 to $2.2 billion, reflecting a $300 million reduction at the high end, primarily driven by timing of deliveries for contracted revenue into the first quarter of 2026
Improves 2025 expected GAAP operating expenses by approximately $400 million to a range of $5.9 to $6.1 billion
Reiterates 2025 expected year-end cash balance of approximately $6 billion
Announced three recent U.S. FDA approvals and positive Phase 3 efficacy results for seasonal influenza vaccine
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025.
“In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine efficacy data and expanded our commercial portfolio with three new U.S. FDA approvals to drive future sales growth,” said Stéphane Bancel, Chief Executive Officer of Moderna. “Today, we are updating our 2025 financial framework, reducing the high end of this year’s expected revenue range by $300 million due to the timing of shipments. We continue to operate with financial discipline and are improving expected annual operating expenses in 2025 by approximately $400 million. Looking forward, we have important catalysts over the next six months across our infectious disease and oncology programs that will help us deliver on the promise of our mRNA platform for patients.”
Recent progress includes:
Commercial Updates
COVID–19: The Company reported $114 million in Spikevax® sales in the second quarter of 2025, which includes $88 million of U.S. sales and $26 million of international sales. Moderna recently announced U.S. Food and Drug Administration (FDA) approval for the supplemental Biologics License Application (sBLA) for Spikevax in children 6 months through 11 years of age who are at increased risk for COVID-19 disease. The Company’s COVID-19 vaccine (mRNA-1273) was previously available for pediatric populations under Emergency Use Authorization (EUA). Additionally, the Company announced it has received final approval from the European Medicines Agency for Spikevax targeting the LP.8.1 variant in individuals six months of age and older. Moderna also announced FDA approval for mNEXSPIKE® (mRNA-1283), a next-generation vaccine against COVID-19, for use in all adults aged 65 and older, as well as individuals aged 12-64 years with at least one underlying risk factor.
RSV: The Company reported negligible mRESVIA® sales in the second quarter of 2025. Moderna’s RSV vaccine for adults aged 60 years and older has been approved in approximately 40 countries. Additionally, Moderna recently announced that the FDA has approved mRESVIA (mRNA-1345), expanding the previous indication, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18-59 years of age who are at increased risk for disease.
Second Quarter 2025 Financial Results
Revenue: Total revenue for the second quarter of 2025 was $142 million, a 41% decrease from $241 million in the same period in 2024. The decline was primarily driven by lower COVID vaccine sales, which totaled $114 million in the quarter. Demand is expected to be concentrated in the second half of the year, aligning with the fall and winter seasons as the vaccine continues to transition into a seasonal respiratory product.
Cost of Sales: Cost of sales for the second quarter of 2025 was $119 million, which included third-party royalties of $6 million, inventory write-downs of $38 million, and unutilized manufacturing capacity and wind-down costs of $52 million. Cost of sales was relatively flat compared to the same period in 2024. The increase in cost of sales as a percentage of net product sales, to 105% from 62% in the second quarter of 2024, was mainly driven by the impact of lower net product sales.
Research and Development Expenses: Research and development expenses for the second quarter of 2025 were $700 million, a 43% decrease compared to the same period in 2024. The reduction was primarily driven by lower clinical trial and manufacturing expenses, reflecting reduced production spending, program wind-downs, and the timing of trial activities across the Company’s respiratory vaccine portfolio.
Selling, General and Administrative Expenses: Selling, general and administrative expenses for the second quarter of 2025 were $230 million, a 14% decrease compared to the same period in 2024. The decline was primarily driven by broad-based cost reductions across consulting and external services, personnel-related expenses, and commercial and marketing activities, reflecting the Company’s continued cost discipline and ongoing efforts to streamline operations.
Income Taxes: Income tax provisions for both periods were not material, as the Company continues to maintain a global valuation allowance against most of its deferred tax assets.
Net Loss: Net loss was $(0.8) billion for the second quarter of 2025, compared to $(1.3) billion for the second quarter of 2024.
Loss Per Share: Loss per share was $(2.13) for the second quarter of 2025, compared to $(3.33) for the second quarter of 2024.
Cash Position: Cash, cash equivalents and investments as of June 30, 2025, were $7.5 billion, compared to $8.4 billion as of March 31, 2025. The decrease during the quarter was primarily due to ongoing research and development expenses and other operating activities.
2025 Financial Framework
Revenue: The Company updated its 2025 projected revenue range to $1.5 to $2.2 billion, reflecting a $300 million reduction at the high end of the range. This is primarily driven by the timing shift of deliveries of contracted revenue for the U.K. into the first quarter of 2026. For the second half of the year, Moderna expects a revenue split of 40-50% in the third quarter with the balance in the fourth quarter of 2025.
Cost of Sales: Cost of sales for 2025 is expected to be approximately $1.2 billion.
Research and Development Expenses: Full-year 2025 research and development expenses are anticipated to be $3.6 to $3.8 billion, lowered from previous expectations of approximately $4.1 billion.
Selling, General and Administrative Expenses: Selling, general and administrative expenses for 2025 are projected to be approximately $1.1 billion.
Income Taxes: The Company continues to expect its full-year tax expense to be negligible.
Capital Expenditures: Capital expenditures for 2025 are expected to be approximately $0.3 billion, lowered from previous expectations of approximately $0.4 billion.
Cash and Investments: Year-end cash and investments for 2025 are projected to be approximately $6 billion.
Recent Progress and Upcoming Late-Stage Pipeline Milestones
Respiratory vaccines:
Seasonal flu vaccine: In June, Moderna announced positive Phase 3 efficacy results for its seasonal flu vaccine (mRNA-1010), which demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older. The Company is submitting mRNA-1010 data for publication, presenting data at medical conferences and preparing to file for FDA approval.
Seasonal flu + COVID vaccine: Moderna shared positive Phase 3 immunogenicity data for its flu/COVID combination vaccine (mRNA-1083) for adults aged 50 years and older at its 2024 R&D Day event. In May 2025, the Company announced that in consultation with the FDA, it had voluntarily withdrawn the pending Biologics License Application (BLA) for mRNA-1083 with the plan to resubmit after vaccine efficacy data from the Phase 3 trial of its investigational seasonal flu vaccine (mRNA-1010) are available. The Company is engaging with regulators on data requirements for resubmitting the BLA for mRNA-1083.
Latent and other vaccines:
Cytomegalovirus (CMV) vaccine: The Company shared 36-month durability data from a Phase 2 extension trial of its CMV vaccine candidate (mRNA-1647) at the ESCMID 2025 Global Congress. The pivotal Phase 3 study of mRNA-1647 is fully enrolled and has now accrued sufficient cases for evaluation of the primary endpoint of the study, evaluating its efficacy, safety and immunogenicity in the prevention of primary infection in women of childbearing age. Moderna is updating its analysis plan to incorporate additional secondary endpoints. The Company remains blinded and anticipates a Phase 3 final analysis in 2025.
Norovirus vaccine: The Phase 3 study evaluating the efficacy, safety and immunogenicity of Moderna’s trivalent vaccine against norovirus (mRNA-1403) is accruing cases. The timing of the Phase 3 readout will be dependent on case accruals.
Oncology therapeutics:
Intismeran autogene: Moderna continues to make progress on advancing mRNA-4157 in the clinic. In collaboration with Merck, the Phase 3 clinical trial for adjuvant melanoma is fully enrolled. Two non-small cell lung cancer (NSCLC) Phase 3 studies for those with and without prior neoadjuvant treatment are enrolling. Separate randomized Phase 2 studies for high-risk muscle invasive and high-risk non-muscle invasive bladder cancer are also enrolling, and a randomized Phase 2 study for adjuvant renal cell carcinoma is fully enrolled. Further, Moderna and Merck have launched a new Phase 2 study of first-line treatment for patients with metastatic melanoma.
Checkpoint adaptive immune modulation therapy (AIM-T): The Phase 1/2 study of mRNA-4359 is ongoing and the Phase 2 study, which includes cohorts in first-line metastatic melanoma and first-line metastatic NSCLC, is enrolling NSCLC patients.
The Company recently announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2025 European Society for Medical Oncology (ESMO) Congress.
Rare disease therapeutics:
Propionic acidemia (PA) therapeutic: In an ongoing Phase 1/2 study designed to evaluate safety and pharmacology in trial participants with PA, Moderna’s investigational therapeutic (mRNA-3927) has been generally well-tolerated to date with no events meeting protocol-defined dose-limiting toxicity criteria. Early results suggest potential decreases in annualized metabolic decompensation event (MDE) frequency compared to pre-treatment, and the majority of patients have elected to continue on the open label extension study. The Company’s PA program is in a registrational study.
Methylmalonic acidemia (MMA) therapeutic: Moderna’s investigational therapeutic for MMA (mRNA-3705) has been selected by the FDA for the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program. The FDA and Moderna have agreed on the pivotal study design. The Company expects to start a registrational study in 2025.
Moderna Corporate Updates
Moderna announced an organizational restructuring that will reduce its global workforce by approximately 10%. The Company anticipates a total headcount of under 5,000 by year-end.
Company Accolades
Moderna was named to the Boston Business Journal‘s annual list of the Most Charitable Companies in Massachusetts (third consecutive year)
Moderna was recognized as a top-scoring company on Disability:IN’s Disability Equality Index and a Best Place to Work for Disability Inclusion (fourth consecutive year)
Key 2025 Investor and Analyst Event Dates
Analyst Day: November 20
Investor Call and Webcast Information
Moderna will host a live conference call and webcast at 8:00 a.m. ET on August 1, 2025. To access the live conference call via telephone, please register at the link below. Once registered, dial-in numbers and a unique pin number will be provided. A live webcast of the call will also be available under “Events and Presentations” in the Investors section of the Moderna website.
The archived webcast will be available on Moderna’s website approximately two hours after the conference call and will be available for one year following the call.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID vaccines.
Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
MODERNA, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, in millions, except per share data)
Three Months Ended June 30,
Six Months Ended June 30,
2025
2024
2025
2024
Revenue:
Net product sales
$
114
$
184
$
200
$
351
Other revenue1
28
57
50
57
Total revenue
142
241
250
408
Operating expenses:
Cost of sales
119
115
209
211
Research and development
700
1,221
1,556
2,284
Selling, general and administrative
230
268
442
542
Total operating expenses
1,049
1,604
2,207
3,037
Loss from operations
(907
)
(1,363
)
(1,957
)
(2,629
)
Interest income
81
111
171
231
Other income (expense), net
8
(27
)
4
(46
)
Loss before income taxes
(818
)
(1,279
)
(1,782
)
(2,444
)
Provision for income taxes
7
–
14
10
Net loss
$
(825
)
$
(1,279
)
$
(1,796
)
$
(2,454
)
Loss per share:
Basic and diluted
$
(2.13
)
$
(3.33
)
$
(4.64
)
$
(6.41
)
Weighted average common shares used in calculation of loss per share:
Basic and diluted
388
384
387
383
_______
1Includes grant, collaboration, licensing and royalty, and other miscellaneous revenue.
MODERNA, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited, in millions)
June 30,
December 31,
2025
2024
Assets
Current assets:
Cash and cash equivalents
$
1,279
$
1,927
Investments
3,852
5,098
Accounts receivable, net
36
358
Inventory
240
117
Prepaid expenses and other current assets
764
599
Total current assets
6,171
8,099
Investments, non-current
2,374
2,494
Property, plant and equipment, net
2,169
2,196
Right-of-use assets, operating leases
750
759
Other non-current assets
546
594
Total assets
$
12,010
$
14,142
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable
$
175
$
405
Accrued liabilities
987
1,427
Deferred revenue
218
153
Other current liabilities
192
221
Total current liabilities
1,572
2,206
Deferred revenue, non-current
65
58
Operating lease liabilities, non-current
666
671
Financing lease liabilities, non-current
32
39
Other non-current liabilities
276
267
Total liabilities
2,611
3,241
Stockholders’ equity:
Additional paid-in capital
1,127
866
Accumulated other comprehensive income (loss)
23
(10
)
Retained earnings
8,249
10,045
Total stockholders’ equity
9,399
10,901
Total liabilities and stockholders’ equity
$
12,010
$
14,142
MODERNA, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited, in millions)
Six Months Ended June 30,
2025
2024
Operating activities
Net loss
$
(1,796
)
$
(2,454
)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation
245
213
Depreciation and amortization
96
77
Amortization/accretion of investments
(37
)
(55
)
Loss on equity investments, net
8
35
Other non-cash items
36
7
Changes in assets and liabilities:
Accounts receivable, net
310
729
Prepaid expenses and other assets
(150
)
3
Inventory
(122
)
(197
)
Right-of-use assets, operating leases
19
(62
)
Accounts payable
(203
)
(199
)
Accrued liabilities
(395
)
(464
)
Deferred revenue
68
146
Operating lease liabilities
(10
)
25
Other liabilities
(25
)
(67
)
Net cash used in operating activities
(1,956
)
(2,263
)
Investing activities
Purchases of marketable securities
(3,059
)
(3,390
)
Proceeds from maturities of marketable securities
3,424
3,536
Proceeds from sales of marketable securities
1,059
1,999
Purchases of property, plant and equipment
(120
)
(378
)
Purchase of intangible asset
(10
)
–
Net cash provided by investing activities
1,294
1,767
Financing activities
Proceeds from issuance of common stock through equity plans
17
47
Tax payments related to net share settlements on equity awards
(1
)
–
Changes in financing lease liabilities
(3
)
1
Net cash provided by financing activities
13
48
Effect of changes in exchange rates on cash and cash equivalents
1
–
Net decrease in cash, cash equivalents and restricted cash
(648
)
(448
)
Cash, cash equivalents and restricted cash, beginning of year
1,929
2,928
Cash, cash equivalents and restricted cash, end of period
$
1,281
$
2,480
Spikevax®, mRESVIA® and mNEXSPIKE® are registered trademarks of Moderna.
Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna’s 2025 financial framework, including its expected revenue range and ending cash balance; Moderna’s expected 2025 operating expenses; demand for Moderna’s products and Moderna’s ability to drive future sales growth; Moderna’s continued cost discipline; and anticipated milestones for Moderna’s pipeline programs, including catalysts over the next six months. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.
###
Moderna Contacts Media: Chris Ridley Head of Global Media Relations +1 617-800-3651 Chris.Ridley@modernatx.com
Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 Lavina.Talukdar@modernatx.com
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna’s EP’949 patent.
This decision affirms the High Court’s initial ruling from July 2024 that the EP’949 patent is valid and infringed by Pfizer/BioNTech’s COVID-19 vaccine, Comirnaty®, which was subsequently appealed by Pfizer/BioNTech. With this ruling, the UK becomes the first jurisdiction globally to issue a second-instance decision confirming the validity of one of Moderna’s core mRNA patents. The High Court’s finding of infringement was not disputed by Pfizer/BioNTech on appeal.
“Moderna is pleased that the Court of Appeal has upheld the High Court’s finding that the EP’949 patent is valid and infringed by Pfizer/BioNTech,” said Moderna Chief Legal Officer Shannon Thyme Klinger. “Moderna will continue to pursue and enforce its patent rights globally to protect its innovative mRNA technology.”
Elsewhere in Europe, recent legal developments have further strengthened Moderna’s intellectual property portfolio:
In Germany, the Regional Court found that Pfizer and BioNTech infringed Moderna’s modified mRNA patent and confirmed Moderna’s right to seek damages. An appeal is pending.
The European Patent Office (EPO) upheld the validity of EP’949 in opposition proceedings, further reinforcing the patent’s strength. An appeal is pending.
European patent EP’949 relates to chemically modified mRNA, one of Moderna’s foundational technologies that enables the development of mRNA-based medicines.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Moderna Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna’s plans to enforce its patent rights globally, including through seeking damages for infringement. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.
– Cash burn of $3.8 million in Q2 remains in line with projected quarterly range
– Cash and investments are sufficient to fund operations through Q3’2026 at current cash burn rate
– Commercial readiness activities underway for a phased launch of VenoValve® subject to FDA decision expected in 2H’2025
– IDE submission for enVVe® on track for 2H’2025
IRVINE, CA / ACCESS Newswire / August 1, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) (“enVVeno Medical” or the “Company”), a company setting new standards of care for the treatment of deep venous disease, today reported financial results for the second quarter 2025.
“As the recent headlines around CVI confirmed, CVI is a pervasive and a progressive disease that is especially debilitating once it becomes severe. Our participation in several of the recent national news stories about CVI fits with our strategy of establishing enVVeno Medical as the world-wide leader in treatments for severe, deep venous disease. With several value driving milestones on the horizon, including FDA decisions on potential approval for the VenoValve and the pivotal study for enVVe, we continue to make strong progress in our mission to bring first-in-category, effective treatments to patients with severe CVI, and are well positioned to lead the ongoing national dialogue about CVI as further events are reported,” commented Robert Berman, CEO of enVVeno Medical.
Summary of Financial Results for the Second Quarter 2025 The Company ended the quarter with $35.1 million in cash and investments. Based on management’s current expectations, this capital has the potential to fund the Company through the third quarter of 2026, including pre-commercialization activities for the VenoValve, and the commencement of the enVVe pivotal study.
Cash burn for the quarter was $3.8 million, consistent with the Company’s projected cash burn rate of approximately $4-5 million per quarter. The Company anticipates that its cash burn rate will increase from current levels once commercialization of the VenoValve begins.
The Company reported net losses of $6.7 million and $5.0 million for the three months ended June 30, 2025 and 2024, respectively, representing an increase in net loss of $1.7 million, or 35%. This increase was primarily due to higher operating expenses of $1.6 million resulting from additional personnel costs, the issuance of option grants, and non-recurring reserve and severance expenses, as well as a decrease in other income of $0.1 million.
Clinical Program Progress VenoValve®: Novel, First-In-Class Surgical Replacement Venous Valve
Amended VenoValve PMA application in response to formal questions from U.S. Food and Drug Administration (FDA)
Continue to respond to FDA questions and inquiries as they arise
Presented positive interm, two-year data at Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting
Successfully completed final wave for the shorter-term subjects in 6-month pre-clinical GLP study
Awaiting final pathology form the GLP study
Successfully completed other testing necessary for IDE filing
IDE filing for enVVe pivotal trial on track for 2H’2025
President Trump CVI Diagnosis Following President Trump’s recent diagnosis of what appears to be moderate CVI, Dr. Marc Glickman, Senior Vice President and Chief Medical Officer of enVVeno Medical was featured in several national television news segments, podcasts, radio reports, and news articles, including Fox News, NewsMax, Morning Wire, and the N.Y. Post. To view this media, click here.
About enVVeno Medical Corporation enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company’s lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe.
Cautionary Note on Forward-Looking Statements This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the “Company”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results and timing may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
SALT LAKE CITY, UT / ACCESS Newswire / July 31, 2025 / tZERO, a pioneer in digitally-native capital markets infrastructure, will launch the tZERO Chain, a next-generation blockchain purpose-built for the compliant issuance, trading and settlement of tokenized real-world assets (RWAs). The launch will also introduce the $TZERO utility token, which will serve as the core transaction and incentive layer for the network.
Leveraging over a decade of leadership in compliant digital securities, tZERO is establishing a blockchain ecosystem that bridges traditional financial markets with the programmable efficiency of decentralized infrastructure. tZERO has long been a pioneer in securities tokenization, and, together with its subsidiaries, operates a leading suite of regulated infrastructure. This includes one of only two special purpose broker-dealers in the U.S. authorized to self-custody digital asset securities and provide clearing for other broker-dealers. tZERO also operates an alternative trading system (ATS), an introducing broker-dealer, a broker-of-record/placement agent for primary capital raisings, and a transfer agent. tZERO is backed by Intercontinental Exchange (ICE), a Fortune 500 company and leading global provider of financial technology and data services, and parent company of the New York Stock Exchange.
Real-world asset tokenization is projected to grow into a multi-trillion-dollar market. Industry reports estimate that over $10 trillion in assets could be tokenized by 2030, including securities, private credit, real estate, collectibles, and luxury goods.
The tZERO Chain is purpose-built to serve a broad spectrum of market participants – including broker-dealers, investment platforms, asset managers, and regulated issuers – with a focus on compliance, scalability, and composability. The network is expected to launch with up to $1 billion in tokenized assets across multiple categories, including tokenized securities, alternative investments, institutional-grade funds, and yield-bearing stablecoin securities. Momentum is expected to accelerate through integrations with regulated financial platforms and tokenization partners.
“Over the past decade, we’ve helped shape the evolution of digital securities and regulated market structure,” said David Goone, CEO of tZERO. “The tZERO Chain is a natural progression of our vision – a compliant, performant, and interoperable blockchain network designed from day one for the tokenization of real-world assets at scale.”
tZERO envisions a future where everything of value can be tokenized – not just securities and funds, but also alternative and illiquid assets such as fine art, classic cars, rare watches, vintage wine, luxury collectibles, real estate, intellectual property, and more. The tZERO Chain is being built to support this universal tokenization thesis on a secure, regulation-friendly platform that integrates natively with common DeFi protocols, expanding global distribution, composability, and liquidity access for compliant digital assets.
Key features of the tZERO Chain include:
Hybrid Public-Permissioned Architecture: Combines open EVM-compatible infrastructure with embedded compliance logic to support both DeFi and regulated finance.
Integrated Regulated Market Infrastructure: Interoperable with the ecosystem operated by tZERO’s broker-dealer subsidiaries in the U.S., including ATS, custody and settlement, as well as transfer agent services.
Cross-Chain Interoperability: Allows tokenized assets to be used, traded, and settled across other leading blockchains – bringing real-world assets into the broader Web3 ecosystem, in compliance with applicable regulations.
DeFi-Enabled RWA Composability: Turns real-world assets into first-class DeFi assets – available for lending, trading, staking, and yield generation.
On-Chain Market Data Layer: Built-in oracles deliver proprietary pricing and analytics for alternative assets such as fine art, collectibles, and luxury goods.
Patent-Protected IP: Enforceable patents for real-time settlement and compliant tokenization provide a defensible technology moat.
The tZERO Chain introduces a novel hybrid model – combining controlled infrastructure with open access for builders and compliant asset issuers. Developers can build on familiar Ethereum tooling while accessing modules for identity verification, compliance disclosures, and asset governance.
“There hasn’t been a blockchain truly purpose-built for compliant asset tokenization – until now,” said tokenization pioneer Stephane De Baets. “With the launch of tZERO Chain and the $TZERO token, we finally have the infrastructure to tokenize real estate and other real-world assets at scale.”
The $TZERO token will be launched as a core part of the network’s infrastructure, powering transactions, smart contracts, governance, and incentives for participants across both traditional and decentralized finance. Details on tokenomics, infrastructure access, and issuance partners will be released in the coming weeks.
This milestone builds upon tZERO’s legacy as a leader in the tokenization of traditional assets and comes at a time when institutional and regulatory interest in blockchain-based infrastructure has reached an inflection point.
tZERO Group, Inc. (tZERO) and its broker-dealer subsidiaries provide an innovative liquidity platform for private companies and assets. We offer institutional-grade solutions for issuers looking to digitize their capital table through blockchain technology, and make such equity available for trading on an alternative trading system. tZERO, through its broker-dealer subsidiaries, democratizes access to private assets by providing a simple, automated, and efficient trading venue to broker-dealers, institutions, and investors. All technology services are offered through tZERO Technologies, LLC. For more information, please visit our website.
About tZERO Digital Asset Securities
tZERO Digital Asset Securities, LLC is a broker-dealer registered with the SEC and a member of FINRA and SIPC. It is the broker-dealer custodian of all digital asset securities offered on tZERO’s online brokerage platform. It operates in accordance with the SEC’s statement, dated December 23, 2020, regarding the Custody of Digital Asset Securities by Special Purpose Broker-Dealers. Digital asset securities may not be “securities” as defined under the Securities Investor Protection Act (SIPA)-and in particular, digital asset securities that are “investment contracts” under the Howey test but are not registered with the Securities and Exchange Commission are excluded from SIPA’s definition of “securities”-and thus the protections afforded to securities customers under SIPA may not apply. More information about tZERO Digital Asset Securities may be found on FINRA’s BrokerCheck.
About tZERO Securities
tZERO Securities, LLC is a broker-dealer registered with the SEC and a member of FINRA and SIPC. It is the operator of the tZERO Securities ATS. More information about tZERO Securities may be found on FINRA’s BrokerCheck.
About tZERO Transfer Services
tZERO Transfer Services, LLC is an SEC-registered transfer agent. More information about tZERO Transfer Services may be found on Edgar.
Investor Notice
Digital asset securities, as well as any particular investment, may not be suitable or appropriate for everyone. Investors should note that investing or trading in securities could involve substantial risks, including no guarantee of returns, costs associated with selling and purchasing, and no assurance of liquidity which could impact their price and investor’s ability to sell, and possible loss of principal invested. There is always the potential of losing money when you invest in securities. There are also unique risks specific to digital asset securities, including, without limitation, fraud, manipulation, theft, and loss. Please see our disclosure library for more information.
No Offer, Solicitation, Investment Advice or Recommendations
This release is for informational purposes only and does not constitute an offer to sell, a solicitation to buy, or a recommendation for any security or other asset (including the potential $TZERO token), nor does it constitute an offer to provide investment advisory or other services by tZERO or any of its affiliates, subsidiaries, officers, directors or employees. No reference to any specific security or another asset constitutes a recommendation to buy, sell, or hold that security or asset or any other security or asset. Nothing in this release shall be considered a solicitation or offer to buy or sell any security, future, option or other financial instrument or to offer or provide any investment advice or service to any person in any jurisdiction. Nothing contained in this release constitutes investment advice or offers any opinion with respect to the suitability of any security or other asset, and the views expressed in this release should not be taken as advice to buy, sell or hold any security or other asset. In preparing the information contained in this release, we have not taken into account the investment needs, objectives, and financial circumstances of any particular investor. This information has no regard to the specific investment objectives, financial situation, and particular needs of any specific recipient of this information and investments discussed may not be suitable for all investors. Any views expressed in this release by us were prepared based upon the information available to us at the time such views were written. Changed or additional information could cause such views to change. All information is subject to possible corrections. Information may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances.
Forward-Looking Statements
This release contains forward-looking statements. In addition, from time to time, tZERO, its subsidiaries, or its representatives may make forward-looking statements orally or in writing. These forward-looking statements are based on expectations and projections about future events, which is derived from currently available information. Such forward-looking statements relate to future events or future performance, including financial performance and projections; growth in revenue and earnings; and business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including, without limitation: the ability of tZERO and its subsidiaries to change the direction; tZERO’s ability to keep pace with new technology and changing market needs; performance of individual transactions; regulatory developments and matters; and competition. These and other factors may cause actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this release and other statements made from time to time by tZERO, its subsidiaries or their respective representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions. tZERO, its subsidiaries, and its representatives are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this release and other statements made from time to time by tZERO, its subsidiaries or its representatives might not occur.
BOSTON, MA / ACCESS Newswire / July 31, 2025 / Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. (“Radius” or the “Company”), a specialty biopharmaceutical company focused on bone health and related areas, announced today that the U.S. District Court for the District of Massachusetts has ruled in favor of Radius and co-plaintiff Ipsen Pharma S.A.S. (“Ipsen”) in a patent infringement suit against Orbicular Pharmaceutical Technologies Private Ltd. (“Orbicular”) for their proposed generic for TYMLOS® (abaloparatide) for osteoporosis. Radius and Ipsen prevailed, and the court upheld the validity of all five TYMLOS® patents asserted, in which the latest to expire will remain in effect through April 30, 2038.
The suit was brought by Radius and Ipsen in September 2022 alleging patent infringement by Orbicular in their attempt to seek FDA approval to market a generic abaloparatide product. Radius asserted that Orbicular’s proposed generic product would infringe five patents held by Radius.
The favorable ruling reinforces the strength of the TYMLOS® patent portfolio and represents an important win for Radius.
About Radius:
Radius is a global biopharmaceutical company dedicated to transforming the future for underserved, global patient populations in bone health and related areas. Radius’ lead product, TYMLOS® (abaloparatide) injection, a parathyroid hormone related peptide, is approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women and men with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture) or patients who have failed or are intolerant to other available osteoporosis therapy. Abaloparatide is supplied as a single-patient multi-use prefilled pen designed to subcutaneously administer 80 micrograms per dose over a 30-day period. For additional information, please visit www.TYMLOS.com.
Flurry of new legislation including OBBBA, GENIUS Act, and aggressive tariff policies creates portfolio rebalancing opportunities amid market volatility
NEW YORK, NY / ACCESS Newswire / July 31, 2025 / The first half of 2025 has delivered an unprecedented wave of legislative changes that are fundamentally reshaping investment strategies across asset classes. The passage of the GENIUS Act on July 18, 2025-the first major cryptocurrency legislation in U.S. history-combined with the sweeping One Big Beautiful Bill Act (OBBBA) signed on July 4, and President Trump’s aggressive tariff implementation beginning with 25% tariffs on Canada and Mexico and 10% on China, has created both opportunity and uncertainty across traditional and alternative investment markets.
“We’re witnessing a once-in-a-generation convergence of policy changes that are forcing institutional investors to completely rethink their allocation strategies,” said Marious Sjulsen, Chief Investment Officer. “While headlines chase crypto euphoria and tariff disruptions, the real opportunity is in the assets everyone else is overlooking.”
The New Legislative Reality
The legislative activity has been nothing short of historic. The Senate voted 68-30 to pass the GENIUS Act, establishing rules for the roughly $238 billion stablecoin market and creating a clearer framework for banks, companies and other entities to issue digital currencies. This crypto-friendly legislation has contributed to Bitcoin and other major cryptocurrencies hitting all-time highs, with the crypto market reaching a record $4 trillion soon after the vote.
Meanwhile, tariff announcements have increased economic policy uncertainty to its highest point since the beginning of the COVID-19 pandemic, with the Economic Policy Uncertainty Index doubling in value from the start of January. The scale of the announcements on April 2nd exceeded economist and market expectations, sending the S&P 500 down over 10% in the two days immediately following.
“The policy shifts we’re seeing are creating massive dislocations across asset classes,” noted Charles Clinton, CEO. “Smart investors aren’t chasing shiny objects. They’re positioning where fundamentals meet opportunity. That intersection is clearly in commercial real estate.”
Investor Behavior Amid Policy Turbulence
Bitcoin hit a record high of $123,153.22 on July 14th, crossing $120,000 for the first time in history. The GENIUS Act’s passage has legitimized stablecoins, with major financial institutions scrambling to enter the market.
But the tariff reality is harsh: companies importing goods face immediate cost increases that historically have been passed to consumers once price levels stabilize. For now, however, companies have been absorbing the tariffs while waiting to see what tariff rates will level at. Technology, materials, energy and industrial sectors-with foreign revenue exposure as high as 57%-are particularly vulnerable to margin compression.
Commercial Real Estate: The Contrarian Play
While markets chase crypto euphoria and panic over tariff disruptions, commercial real estate presents a compelling contrarian opportunity. The sector combines favorable valuations, robust policy tailwinds, and fundamental recovery indicators-a rare trifecta in today’s volatile environment.
Bottom-Cycle Valuations: Industry experts believe values hit the bottom at the end of 2024 after falling 20%-40% from peak levels. At the same time, core transactions traded at 20% to 25% discounts to 2021 valuations, which created compelling entry points for patient capital.
Legislative Rocket Fuel: The OBBBA delivers substantial benefits. 100% bonus depreciation is permanently restored for property acquired and placed in service after January 19, 2025. The Qualified Opportunity Zone program becomes permanent, with enhanced rural investment benefits offering 30% basis step-ups after five years.
“We’re seeing institutional capital flood toward real assets with built-in tax advantages and defensive characteristics,” said Sjulsen. “While everyone’s focused on Bitcoin hitting new highs, we’re buying cash-flowing properties at generational discounts with permanent tax benefits.”
The legislative whirlwind has created significant market dislocations favoring patient capital in real assets. Since Q4 2024, commercial real estate activity has increased-lending standards are loosening, price discovery is recovering, and asset write-downs are decreasing.
Yet policy uncertainty keeps most investors on the sidelines. The numbers tell the story: Blackstone sits on over $62 billion in inflows with $177 billion of dry powder. TPG and Brookfield have similar war chests waiting for deployment.
“The institutions with the biggest checkbooks aren’t chasing crypto at all-time highs or trying to navigate tariff chaos,” observed Clinton. “They’re positioning for the CRE recovery that’s already underway but hasn’t been recognized by the broader market yet.”
Fundamental Recovery Gaining Momentum
CRE fundamentals are strengthening across sectors, even as media attention focuses elsewhere:
In Q2 2025, industrial leasing activity improved 4.2% year-over-year despite economic headwinds and muted net absorption
CBRE projects that the absence of meaningful new supply in the retail sector will result in low vacancy levels, opening the door to above-inflation rent growth
The office sector has continued to recover; Cushman & Wakefield notes that the four-quarter rolling absorption total improved for the fifth quarter in a row, up 49% year-over-year
“The recovery isn’t coming-it’s here,” said Sjulsen. “While markets obsess over regulatory clarity for stablecoins, we’re seeing occupancy rates climb and rent growth return across our portfolio.”
The Strategic Rotation Case
The current environment presents textbook conditions for rotating from overheated growth assets toward undervalued real assets with policy support.
The Trade:
Crypto benefits from regulatory clarity but trades at extreme valuations
Growth sectors face tariff headwinds and margin compression
Commercial real estate combines attractive entry points with enhanced tax benefits
Interest rate increases have already been reflected in current CRE pricing
“This isn’t about timing the market-it’s about recognizing value,” said Clinton. “When you can buy stabilized real estate at 25% discounts with permanent tax advantages while Bitcoin trades at all-time highs, the allocation decision makes itself.”
The Bottom Line
Real estate organizations have a generational opportunity to capitalize on legislative support, market-bottom valuations, and institutional capital deployment. The combination of OBBBA’s permanent tax advantages, sector fundamentals recovery, and pricing dislocations suggests commercial real estate is positioned for outperformance.
“The next cycle always begins when everyone’s looking the other way,” concluded Sjulsen. “While the market debates crypto regulation and tariff impacts, we’re building positions in cash-flowing assets with permanent tax advantages. That’s how generational wealth gets built.”
As the investment landscape adapts to new legislative realities, the winners will be those who can navigate beyond headline volatility to identify fundamental value in real assets. Commercial real estate-with enhanced tax treatment, attractive valuations, and recovering fundamentals-presents a compelling case for strategic portfolio allocation in today’s environment.
About EquityMultiple EquityMultiple’s mission is to guide investors toward a stronger, more diversified portfolio. EquityMultiple brings accredited investors curated real estate private equity and private credit offerings, broadening and streamlining access to CRE. Founded in 2015, EquityMultiple has distributed over $478 million to investors with assets across 148 distinct markets in the U.S.. For more information, visit equitymultiple.com.
EM Advisor, LLC (“EquityMultiple”), is an SEC registered investment advisor. Information within this report may have been provided by third-parties and, while EquityMultiple believes this information to be accurate, EquityMultiple has not independently verified such information. Reference to registration with the Securities and Exchange Commission (“SEC”) does not imply that the SEC has endorsed or approved the qualifications of the firm or its respective representatives to provide any advisory services described on the report or that the Firm has attained a level of skill or training. The opinions expressed herein are those of the individual speakers and do not necessarily reflect the opinions of EquityMultiple. Investing in securities involves risks, and there is always the potential of losing money when you invest in securities.
For more information about EquityMultiple, including our services, fees, and conflicts of interest, please refer to our Form ADV Part 2A, which is available upon request or by visiting https://adviserinfo.sec.gov/firm/summary/314402
Company resumes trading under “VINO” amid Argentina’s economic stabilization and U.S. partnership momentum
MIAMI, FL / ACCESS Newswire / July 31, 2025 / Gaucho Group Holdings, Inc. (OTC:VINO), a company that includes a growing collection of e-commerce platforms with a concentration on fine wines, luxury real estate, and leather goods and accessories (the “Company” or “Gaucho Holdings”), announced today that the “Q” designation has been officially removed from its trading symbol. Effective immediately, the Company’s shares will resume trading under the symbol VINO on the OTC Markets.
The “Q” suffix was initially added to the VINO trading symbol in November 2024 following Gaucho Holdings’ voluntary Chapter 11 filing. On June 16, 2025, the Company successfully emerged from Chapter 11 under court approval. In the weeks since, Gaucho Holdings has undertaken and completed the necessary steps to reinstate its trading symbol to VINO.
In parallel with this development, the Company has engaged an independent public accounting firm, CBIZ, Inc., to audit its financial statements. This includes the preparation and filing of its Form 10-K for the fiscal year ended December 31, 2024, as well as its 10-Q filings for 2025. Gaucho Holdings is working to regain full reporting compliance within approximately 90 days, which is expected to facilitate broader investor engagement and enhance trading opportunities on the OTC marketplace.
This milestone occurs as Argentina experiences significant macroeconomic changes under the administration of President Javier Milei. Over the past 18 months, inflation has declined by more than 95%, with additional improvement anticipated into 2026. Gaucho Holdings continues to monitor these economic developments, which coincide with increased U.S.-Argentina economic cooperation and interest in key sectors where the Company is active, including wine, tourism, and luxury goods.
“The removal of the ‘Q’ symbol is an important achievement for Gaucho Holdings and a clear signal that we have emerged from the Chapter 11 reorganization,” said Scott Mathis, CEO and Founder of Gaucho Group Holdings, Inc. “We remain focused on rebuilding stockholder confidence through operational transparency and financial integrity. At the same time, we are operating in a moment of significant change and optimism in Argentina, where our businesses are rooted. We look forward to continuing to align our strategy with the country’s evolving economic landscape.”
For more than ten years, Gaucho Group Holdings, Inc.’s (gauchoholdings.com) mission has been to source and develop opportunities in Argentina’s undervalued luxury real estate and consumer marketplace. Our company has positioned itself to take advantage of the continued and fast growth of global e-commerce across multiple market sectors, with the goal of becoming a leader in diversified luxury goods and experiences in sought after lifestyle industries and retail landscapes. With a concentration on fine wines (algodonfinewines.com & algodonwines.com.ar), hospitality (algodonhotels.com), and luxury real estate (algodonwineestates.com) associated with our proprietary Algodon brand, as well as the leather goods, ready-to-wear and accessories of the fashion brand Gaucho – Buenos Aires® (gaucho.com), these are the luxury brands in which Argentina finds its contemporary expression.
The information discussed in this press release includes “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included herein concerning, among other things, changes to exchange rates and their impact on the Company, planned capital expenditures, future cash flows and borrowings, pursuit of potential acquisition opportunities, our financial position, business strategy and other plans and objectives for future operations, are forward-looking statements. Although we believe that the expectations reflected in these forward-looking statements are reasonable, they do involve certain assumptions, risks and uncertainties and are not (and should not be considered to be) guarantees of future performance. Refer to our risk factors set forth in our reports filed on Edgar. The Company disclaims any obligation to update any forward-looking statement made here.
NEW YORK CITY, NY / ACCESS Newswire / July 31, 2025 / IPOMarket.com, the digital media platform focused on high-impact pre-IPO and IPO coverage, announces exclusive feature coverage of the red-hot FIGMA IPO – widely regarded as one of the most anticipated tech offerings of the decade.
With a projected valuation exceeding $30 billion, FIGMA’s public debut marks a major milestone in the evolution of collaborative design and productivity software. The platform’s browser-based model and deep enterprise penetration position it as a breakout player in the new era of AI-enhanced SaaS solutions.
The IPOMarket.com special feature offers a deep dive into FIGMA’s journey from startup to standout – exploring its competitive moat, product-market fit, and revenue velocity leading into the offering.
“This IPO isn’t just about valuation – it’s about signaling where the next generation of enterprise innovation is heading,” said Stephen Simon, Co-Founder of IPOMarket.com and New to The Street. “FIGMA’s story reflects the growing power of cloud-first, collaboration-first platforms – and we’re proud to bring investors a clear and compelling view of that trajectory.”
The upcoming commentary will be featured across New to The Street’s comprehensive media platform, including national network television, targeted social media, and the fastest-growing YouTube channel in the investor space – New to The Street TV, now surpassing 3.2 million subscribers.
This exclusive coverage is part of IPOMarket.com‘s broader mission to demystify the public offering process and spotlight companies shaping the financial future.
For media inquiries, contact: Grace Bongiorno Communications | IPOMarket.com / New to The Street Grace@NewToTheStreet.com
LOS ANGELES, CA / ACCESS Newswire / July 31, 2025 / The Florida Legislature has approved $20 million in new funding for the Florida Tutoring Advantage grant, a statewide initiative aimed at boosting student achievement in reading and math for K-5 public school students.
Backed by House Bill 1361 (2024) and administered by the University of Florida’s Lastinger Center for Learning, the Florida Tutoring Advantage grant empowers districts and schools to provide high-impact tutoring through state-approved providers. HeyTutor, one of the only vendors offering dedicated in-person tutoring statewide, is prepared to help schools deliver effective, research-based instruction where it matters most – directly in the classroom.
“Research consistently shows that in-person tutoring leads to stronger engagement and better outcomes for young learners,” said Jennifer Sheffield, CEO at HeyTutor. “With this historic funding, we encourage districts to prioritize in-person support for K-5 learners that meets students where they are and keeps them connected to caring, qualified tutors.”
While the grant allows for virtual and digital delivery models, HeyTutor stands out as one of the few providers equipped to offer face-to-face, high-dosage tutoring at scale. With deep experience working with schools and districts nationwide, HeyTutor customizes tutoring programs to align with state standards and district goals, tracking progress to ensure measurable results.
The $20 million funding allocation underscores Florida’s commitment to investing in early learning recovery and achievement. In partnership with the University of Florida’s Lastinger Center for Learning, Districts can now move quickly to launch or expand tutoring initiatives that directly support struggling students in foundational reading and math.
HeyTutor is actively partnering with schools to build flexible, scalable tutoring programs that prioritize human connection, academic rigor, and measurable growth.
